188 related articles for article (PubMed ID: 32267900)
1. Interplay between TERT promoter mutations and methylation culminates in chromatin accessibility and TERT expression.
Salgado C; Roelse C; Nell R; Gruis N; van Doorn R; van der Velden P
PLoS One; 2020; 15(4):e0231418. PubMed ID: 32267900
[TBL] [Abstract][Full Text] [Related]
2. Characterization of Allele-Specific Regulation of Telomerase Reverse Transcriptase in Promoter Mutant Thyroid Cancer Cell Lines.
McKelvey BA; Gilpatrick T; Wang Y; Timp W; Umbricht CB; Zeiger MA
Thyroid; 2020 Oct; 30(10):1470-1481. PubMed ID: 32228178
[No Abstract] [Full Text] [Related]
3. Pervasive promoter hypermethylation of silenced TERT alleles in human cancers.
Esopi D; Graham MK; Brosnan-Cashman JA; Meyers J; Vaghasia A; Gupta A; Kumar B; Haffner MC; Heaphy CM; De Marzo AM; Meeker AK; Nelson WG; Wheelan SJ; Yegnasubramanian S
Cell Oncol (Dordr); 2020 Oct; 43(5):847-861. PubMed ID: 32468444
[TBL] [Abstract][Full Text] [Related]
4. Characterization of human telomerase reverse transcriptase promoter methylation and transcription factor binding in differentiated thyroid cancer cell lines.
Avin BA; Wang Y; Gilpatrick T; Workman RE; Lee I; Timp W; Umbricht CB; Zeiger MA
Genes Chromosomes Cancer; 2019 Aug; 58(8):530-540. PubMed ID: 30664813
[TBL] [Abstract][Full Text] [Related]
5. Allele-Specific DNA Methylation and Its Interplay with Repressive Histone Marks at Promoter-Mutant TERT Genes.
Stern JL; Paucek RD; Huang FW; Ghandi M; Nwumeh R; Costello JC; Cech TR
Cell Rep; 2017 Dec; 21(13):3700-3707. PubMed ID: 29281820
[TBL] [Abstract][Full Text] [Related]
6. Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behavior of bladder cancer.
Leão R; Lee D; Figueiredo A; Hermanns T; Wild P; Komosa M; Lau I; Mistry M; Nunes NM; Price AJ; Zhang C; Lipman T; Poyet C; Valtcheva N; Oehl K; Coelho H; Sayyid R; Gomes AM; Prado E Castro L; Sweet J; Vinagre J; Apolónio J; Stephens D; Faleiro I; Fadaak K; Richard PO; Kulkarni G; Zlotta AR; Hamilton RJ; Castelo-Branco P; Tabori U
Int J Cancer; 2019 Apr; 144(7):1676-1684. PubMed ID: 30350309
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity of telomerase reverse transcriptase mutation and expression, telomerase activity and telomere length across human cancer cell lines cultured in vitro.
Dratwa M; Wysoczanska B; Turlej E; Anisiewicz A; Maciejewska M; Wietrzyk J; Bogunia-Kubik K
Exp Cell Res; 2020 Nov; 396(1):112298. PubMed ID: 32971118
[TBL] [Abstract][Full Text] [Related]
8. Allele-specific proximal promoter hypomethylation of the telomerase reverse transcriptase gene (TERT) associates with TERT expression in multiple cancers.
Rowland TJ; Bonham AJ; Cech TR
Mol Oncol; 2020 Oct; 14(10):2358-2374. PubMed ID: 33245585
[TBL] [Abstract][Full Text] [Related]
9. TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations.
Labussière M; Di Stefano AL; Gleize V; Boisselier B; Giry M; Mangesius S; Bruno A; Paterra R; Marie Y; Rahimian A; Finocchiaro G; Houlston RS; Hoang-Xuan K; Idbaih A; Delattre JY; Mokhtari K; Sanson M
Br J Cancer; 2014 Nov; 111(10):2024-32. PubMed ID: 25314060
[TBL] [Abstract][Full Text] [Related]
10. Acquired TERT promoter mutations stimulate TERT transcription in mantle cell lymphoma.
Panero J; Alves-Paiva RM; Roisman A; Santana-Lemos BA; Falcão RP; Oliveira G; Martins D; Stanganelli C; Slavutsky I; Calado RT
Am J Hematol; 2016 May; 91(5):481-5. PubMed ID: 26852175
[TBL] [Abstract][Full Text] [Related]
11. Telomerase Reverse Transcriptase Promoter Mutations in Human Hepatobiliary, Pancreatic and Gastrointestinal Cancer Cell Lines.
Hirata M; Fujita K; Fujihara S; Mizuo T; Nakabayashi R; Kono T; Namima D; Fujita N; Yamana H; Kamada H; Tani J; Kobara H; Tsutsui K; Matsuda Y; Ono M; Masaki T
In Vivo; 2022; 36(1):94-102. PubMed ID: 34972704
[TBL] [Abstract][Full Text] [Related]
12. TERT promoter mutations in familial and sporadic melanoma.
Horn S; Figl A; Rachakonda PS; Fischer C; Sucker A; Gast A; Kadel S; Moll I; Nagore E; Hemminki K; Schadendorf D; Kumar R
Science; 2013 Feb; 339(6122):959-61. PubMed ID: 23348503
[TBL] [Abstract][Full Text] [Related]
13. ETS Factor ETV5 Activates the Mutant Telomerase Reverse Transcriptase Promoter in Thyroid Cancer.
Bullock M; Lim G; Zhu Y; Åberg H; Kurdyukov S; Clifton-Bligh R
Thyroid; 2019 Nov; 29(11):1623-1633. PubMed ID: 31452441
[No Abstract] [Full Text] [Related]
14. Exploring the epigenetic regulation of telomerase reverse transcriptase (TERT) in human cancer cell lines.
McKelvey BA; Zeiger MA; Umbricht CB
Mol Oncol; 2020 Oct; 14(10):2355-2357. PubMed ID: 32920953
[TBL] [Abstract][Full Text] [Related]
15. CTCF mediates the TERT enhancer-promoter interactions in lung cancer cells: identification of a novel enhancer region involved in the regulation of TERT gene.
Eldholm V; Haugen A; Zienolddiny S
Int J Cancer; 2014 May; 134(10):2305-13. PubMed ID: 24174344
[TBL] [Abstract][Full Text] [Related]
16. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA.
Wang N; Liu T; Sofiadis A; Juhlin CC; Zedenius J; Höög A; Larsson C; Xu D
Cancer; 2014 Oct; 120(19):2965-79. PubMed ID: 24898513
[TBL] [Abstract][Full Text] [Related]
17. Telomerase activation in small intestinal neuroendocrine tumours is associated with aberrant
Fotouhi O; Ghaderi M; Wang N; Zedenius J; Kjellman M; Xu D; Juhlin CC; Larsson C
Epigenetics; 2019 Dec; 14(12):1224-1233. PubMed ID: 31322481
[TBL] [Abstract][Full Text] [Related]
18. New somatic TERT promoter variants enhance the Telomerase activity in Glioblastoma.
Pierini T; Nardelli C; Lema Fernandez AG; Pierini V; Pellanera F; Nofrini V; Gorello P; Moretti M; Arniani S; Roti G; Giovenali P; Lupattelli M; Metro G; Molica C; Castrioto C; Corinaldesi R; Laurenti ME; Ascani S; Mecucci C; La Starza R
Acta Neuropathol Commun; 2020 Aug; 8(1):145. PubMed ID: 32843091
[TBL] [Abstract][Full Text] [Related]
19. Differential TERT promoter methylation and response to 5-aza-2'-deoxycytidine in acute myeloid leukemia cell lines: TERT expression, telomerase activity, telomere length, and cell death.
Pettigrew KA; Armstrong RN; Colyer HA; Zhang SD; Rea IM; Jones RE; Baird DM; Mills KI
Genes Chromosomes Cancer; 2012 Aug; 51(8):768-80. PubMed ID: 22517724
[TBL] [Abstract][Full Text] [Related]
20. Craniopharyngiomas, including Recurrent Cases, Lack TERT Promoter Hotspot Mutations.
Fujio S; Juratli TA; Takajo T; Arita K; Nagano Y; Yoshimoto K; Nayyar N; Curry WT; Martinez-Lage M; Cahill DP; Barker FG; Brastianos PK
Neurol Med Chir (Tokyo); 2021 Jun; 61(6):385-391. PubMed ID: 33967180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]